Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain

Jin H. Park, Yingting Liu, Mark A. Lemmon et al. · Biochemical Journal · 2012 · 403 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer

Xin Li, Changyong Yang, Hong Wan et al. · European Journal of Pharmaceutical Sciences · 2017 · 227 citations

Medicine, Medicinal Chemistry, Oncology +13

Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-<i>d</i>]pyrimidine Scaffold

Tomoyasu Ishikawa, Masaki Seto, Hiroshi Banno et al. · Journal of Medicinal Chemistry · 2011 · 216 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives as EGFR TK inhibitors and potential anticancer agents

Peng‐Cheng Lv, Dong‐Dong Li, Qing‐Shan Li et al. · Bioorganic & Medicinal Chemistry Letters · 2011 · 163 citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +17

Synthesis of novel substituted 1,3-diaryl propenone derivatives and their antimalarial activity in vitro

Nidhi Mishra, Preeti Arora, Brajesh Kumar et al. · European Journal of Medicinal Chemistry · 2007 · 146 citations

Pharmacy, Medicinal Chemistry, Pharmacology +10